WntResearch provides update on the clinical development of the drug candidate Foxy-5
WntResearch today announced that the last of totally 12 patients has been included in the dose-ranging part of a Phase 1b study with the drug candidate Foxy-5. This is expected to enable a decision this spring on the dose level for the planned Phase 2 study. Furthermore, a retrospective tumor sample study, whose results will be important in defining the continued development route for Foxy-5, has been initiated.
In preclinical models, Foxy-5 has been shown to reduce tumor cell mobility, thus preventing the emergence of metastases. In the ongoing Phase 1b study, the drug candidate is evaluated in patients with colon, prostate or breast cancer. Signals on biological effect that could form the basis for dose-setting has already been observed in the study.
It is expected that a decision about the appropriate dose for the planned Phase 2 study can be made based on results from the dose-ranging part of the Phase 1b study, where a total of 12 patients receives Foxy-5 at four different dose levels. In the concluding part (expansion group) of the Phase 1b study, three patients will be treated with the dose selected for the Phase 2 study.
"We are now looking forward to complete the Phase 1b study and define the dose for the future Phase 2 study, which is expected to start later this year. It is very gratifying that we already have been able to establish a biological effect of this unique drug candidate against tumor spread," says Henrik Lawaetz, CEO, WntResearch AB.
Another important foundation for defining the design of the Phase 2 trial is the future result of a retrospective study of tumor samples from colon and rectal cancer patients. The study was recently approved by authorities, and has now commenced.
For further information, contact:
Henrik Lawaetz, CEO
Telephone: +46 72 702 4694
This information is information that WntResearch AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 CET on February 21 2017.
WntResearch is developing a new type of cancer treatment based on pioneering research, which shows that the endogenous protein Wnt-5a plays a crucial role for tumour cells’ ability to relocate and spread in the body. Most patients that die of cancer do so not due to the primary tumour, but due to metastases. The need for a specific treatment to counteract metastasis is therefore in high demand.
WntResearch’s most advanced drug candidate Foxy-5 has in preclinical tests been shown to reduce tumour cells’ mobility and thereby counteract the occurrence of metastases. The results from a completed phase 1 study show a favourable safety and pharmacokinetic profile, as well as early indications of biological activity. A phase 1b study is currently ongoing in patients with cancer of the colon, prostate and breast. WntResearch is a public company listed at AktieTorget in Stockholm, Sweden.
For further information: www.wntresearch.com